Modality
Gene Editing
MOA
Anti-Tau
Target
BCMA
Pathway
Epigenetic
Parkinson'sPsA
Development Pipeline
Preclinical
~Mar 2015
→ ~Jun 2016
Phase 1
~Sep 2016
→ ~Dec 2017
Phase 2
Mar 2018
→ Sep 2030
Phase 2Current
NCT06317078
69 pts·PsA
2018-03→2030-09·Recruiting
NCT06253313
2,287 pts·Parkinson's
2019-05→2029-05·Completed
2,356 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-05-153.1y awayPh2 Data· Parkinson's
2030-09-254.5y awayPh2 Data· PsA
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2
Recruit…
P2
Complet…
Catalysts
Ph2 Data
2029-05-15 · 3.1y away
Parkinson's
Ph2 Data
2030-09-25 · 4.5y away
PsA
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06317078 | Phase 2 | PsA | Recruiting | 69 | EASI-75 |
| NCT06253313 | Phase 2 | Parkinson's | Completed | 2287 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA |